Harmony Biosciences Holdings, Inc. $HRMY Stock: Profund Advisors LLC Boosts Stake

Harmony Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Profund Advisors increased its Harmony Biosciences stake by 311.7% in the third quarter, reaching 39,094 shares valued at approximately $1.54 million. Institutional investors collectively own 86.23% of HRMY.
  • Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $48.00; Zacks upgraded the stock to “Strong Buy.”
  • HRMY shares opened at $37.91, down 2.2%, while the company’s latest quarter exceeded expectations with $1.28 in EPS and $261.28 million in revenue, up 30.3% year over year.
  • Five stocks we like better than Harmony Biosciences.

Profund Advisors LLC grew its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 311.7% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 39,094 shares of the company's stock after buying an additional 29,599 shares during the period. Profund Advisors LLC owned approximately 0.07% of Harmony Biosciences worth $1,535,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC lifted its stake in shares of Harmony Biosciences by 166.7% in the third quarter. Farther Finance Advisors LLC now owns 816 shares of the company's stock valued at $32,000 after buying an additional 510 shares during the period. Nykredit A S bought a new position in Harmony Biosciences during the second quarter valued at about $33,000. Signaturefd LLC increased its stake in Harmony Biosciences by 200.0% during the third quarter. Signaturefd LLC now owns 1,686 shares of the company's stock valued at $66,000 after acquiring an additional 1,124 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Harmony Biosciences in the 2nd quarter valued at approximately $65,000. Finally, Allworth Financial LP acquired a new position in Harmony Biosciences in the 2nd quarter valued at approximately $71,000. Institutional investors own 86.23% of the company's stock.

Wall Street Analyst Weigh In

HRMY has been the subject of a number of research reports. Zacks Research upgraded Harmony Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 15th. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, October 13th. Truist Financial upped their target price on Harmony Biosciences from $29.00 to $34.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. WBB Securities upgraded Harmony Biosciences to a "hold" rating in a research note on Friday, October 23rd. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Harmony Biosciences in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $48.00.

Get Our Latest Research Report on Harmony Biosciences

Insider Activity

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the business's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider owned 13,115 shares of the company's stock, valued at approximately $564,600.75. The trade was a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 72,406 shares of company stock valued at $3,108,520 in the last three months. Insiders own 11.00% of the company's stock.

Harmony Biosciences Stock Down 2.2%

Shares of HRMY opened at $37.91 on Tuesday. The company has a quick ratio of 3.45, a current ratio of 3.48 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $39.76 and a two-hundred day moving average price of $34.74. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of 12.31, a P/E/G ratio of 0.31 and a beta of 1.01. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.90 and a 12 month high of $43.49.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%. The company had revenue of $261.28 million during the quarter, compared to analysts' expectations of $250.77 million. During the same period last year, the business earned $0.92 earnings per share. The business's revenue was up 30.3% on a year-over-year basis. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 3.73 EPS for the current fiscal year.

Harmony Biosciences Profile

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company's activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony's principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.

Further Reading

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Harmony Biosciences Right Now?

Before you consider Harmony Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.

While Harmony Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines